Beyond Tumor Mutation Burden: Tumor Neoantigen Burden As a Biomarker for Immunotherapy and Other Types of Therapy

Overview

Journal Front Oncol

Specialty Oncology

Date 2021 May 17

PMID 33996601

Citations 64

Authors

Peipei Wang

Yueyun Chen

Chun Wang

Affiliations

Soon will be listed here.

Abstract

Immunotherapy has significantly improved the clinical outcome of patients with cancer. However, the immune response rate varies greatly, possibly due to lack of effective biomarkers that can be used to distinguish responders from non-responders. Recently, clinical studies have associated high tumor neoantigen burden (TNB) with improved outcomes in patients treated with immunotherapy. Therefore, TNB has emerged as a biomarker for immunotherapy and other types of therapy. In the present review, the potential application of TNB as a biomarker was evaluated. The methods of neoantigen prediction were summarized and the mechanisms involved in TNB were investigated. The impact of high TNB and increased number of infiltrating immune cells on the efficacy of immunotherapy was also addressed. Finally, the future challenges of TNB were discussed.

Citing Articles

Advances in Immunotherapy in Hepatocellular Carcinoma.

Bloom M, Podder S, Dang H, Lin D Int J Mol Sci. 2025; 26(5).

PMID: 40076561 PMC: 11900920. DOI: 10.3390/ijms26051936.

A comprehensive pan-cancer analysis of RNF187 in human tumors.

Zhang X, Zhang X, Liu T, Sha K Discov Oncol. 2025; 16(1):37.

PMID: 39804497 PMC: 11730043. DOI: 10.1007/s12672-025-01795-x.

Advancements in immunotherapy for colorectal cancer treatment: a comprehensive review of strategies, challenges, and future prospective.

Kaviyarasan V, Das A, Deka D, Saha B, Banerjee A, Sharma N Int J Colorectal Dis. 2024; 40(1):1.

PMID: 39731596 PMC: 11682016. DOI: 10.1007/s00384-024-04790-w.

In silico neoantigen screening and HLA multimer-based validation identify immunogenic neopeptide in multifocal lung adenocarcinoma.

Wang X, Jiang L, Zhao J, Wu M, Xiong J, Wu X Front Immunol. 2024; 15:1456209.

PMID: 39720721 PMC: 11666526. DOI: 10.3389/fimmu.2024.1456209.

A novel immune-related gene prognostic signature combining immune cell infiltration and immune checkpoint for glioblastoma patients.

Liu X, Liu X Transl Cancer Res. 2024; 13(11):6136-6153.

PMID: 39697704 PMC: 11651773. DOI: 10.21037/tcr-24-562.

References

Jia Q, Wu W, Wang Y, Alexander P, Sun C, Gong Z . Local mutational diversity drives intratumoral immune heterogeneity in non-small cell lung cancer. Nat Commun. 2018; 9(1):5361. PMC: 6299138. DOI: 10.1038/s41467-018-07767-w. View

Liu G, Li D, Li Z, Qiu S, Li W, Chao C . PSSMHCpan: a novel PSSM-based software for predicting class I peptide-HLA binding affinity. Gigascience. 2017; 6(5):1-11. PMC: 5467046. DOI: 10.1093/gigascience/gix017. View

Rosenberg S, Restifo N . Adoptive cell transfer as personalized immunotherapy for human cancer. Science. 2015; 348(6230):62-8. PMC: 6295668. DOI: 10.1126/science.aaa4967. View

Ballhausen A, Przybilla M, Jendrusch M, Haupt S, Pfaffendorf E, Seidler F . The shared frameshift mutation landscape of microsatellite-unstable cancers suggests immunoediting during tumor evolution. Nat Commun. 2020; 11(1):4740. PMC: 7506541. DOI: 10.1038/s41467-020-18514-5. View

Mariathasan S, Turley S, Nickles D, Castiglioni A, Yuen K, Wang Y . TGFβ attenuates tumour response to PD-L1 blockade by contributing to exclusion of T cells. Nature. 2018; 554(7693):544-548. PMC: 6028240. DOI: 10.1038/nature25501. View

Chae Y, Anker J, Bais P, Namburi S, Giles F, Chuang J . Mutations in DNA repair genes are associated with increased neo-antigen load and activated T cell infiltration in lung adenocarcinoma. Oncotarget. 2018; 9(8):7949-7960. PMC: 5814272. DOI: 10.18632/oncotarget.23742. View

Wang X, Ricciuti B, Nguyen T, Li X, Rabin M, Awad M . Association between Smoking History and Tumor Mutation Burden in Advanced Non-Small Cell Lung Cancer. Cancer Res. 2021; 81(9):2566-2573. PMC: 8137661. DOI: 10.1158/0008-5472.CAN-20-3991. View

Lawrence M, Stojanov P, Polak P, Kryukov G, Cibulskis K, Sivachenko A . Mutational heterogeneity in cancer and the search for new cancer-associated genes. Nature. 2013; 499(7457):214-218. PMC: 3919509. DOI: 10.1038/nature12213. View

Johanns T, Miller C, Liu C, Perrin R, Bender D, Kobayashi D . Detection of neoantigen-specific T cells following a personalized vaccine in a patient with glioblastoma. Oncoimmunology. 2019; 8(4):e1561106. PMC: 6422384. DOI: 10.1080/2162402X.2018.1561106. View

10.

Harari A, Graciotti M, Bassani-Sternberg M, Kandalaft L . Antitumour dendritic cell vaccination in a priming and boosting approach. Nat Rev Drug Discov. 2020; 19(9):635-652. DOI: 10.1038/s41573-020-0074-8. View

11.

Salewski I, Gladbach Y, Kuntoff S, Irmscher N, Hahn O, Junghanss C . In vivo vaccination with cell line-derived whole tumor lysates: neoantigen quality, not quantity matters. J Transl Med. 2020; 18(1):402. PMC: 7579816. DOI: 10.1186/s12967-020-02570-y. View

12.

Gubin M, Zhang X, Schuster H, Caron E, Ward J, Noguchi T . Checkpoint blockade cancer immunotherapy targets tumour-specific mutant antigens. Nature. 2014; 515(7528):577-81. PMC: 4279952. DOI: 10.1038/nature13988. View

13.

Hu Z, Ott P, Wu C . Towards personalized, tumour-specific, therapeutic vaccines for cancer. Nat Rev Immunol. 2017; 18(3):168-182. PMC: 6508552. DOI: 10.1038/nri.2017.131. View

14.

McGranahan N, Rosenthal R, Hiley C, Rowan A, Watkins T, Wilson G . Allele-Specific HLA Loss and Immune Escape in Lung Cancer Evolution. Cell. 2017; 171(6):1259-1271.e11. PMC: 5720478. DOI: 10.1016/j.cell.2017.10.001. View

15.

Simnica D, Akyuz N, Schliffke S, Mohme M, V Wenserski L, Mahrle T . T cell receptor next-generation sequencing reveals cancer-associated repertoire metrics and reconstitution after chemotherapy in patients with hematological and solid tumors. Oncoimmunology. 2019; 8(11):e1644110. PMC: 6791461. DOI: 10.1080/2162402X.2019.1644110. View

16.

Green A, Aleskandarany M, Ali R, Hodgson E, Atabani S, De Souza K . Clinical Impact of Tumor DNA Repair Expression and T-cell Infiltration in Breast Cancers. Cancer Immunol Res. 2017; 5(4):292-299. DOI: 10.1158/2326-6066.CIR-16-0195. View

17.

Blaeschke F, Paul M, Schuhmann M, Rabsteyn A, Schroeder C, Casadei N . Low mutational load in pediatric medulloblastoma still translates into neoantigens as targets for specific T-cell immunotherapy. Cytotherapy. 2019; 21(9):973-986. DOI: 10.1016/j.jcyt.2019.06.009. View

18.

Chae Y, Viveiros P, Lopes G, Sukhadia B, Sheikh M, Saravia D . Clinical and Immunological Implications of Frameshift Mutations in Lung Cancer. J Thorac Oncol. 2019; 14(10):1807-1817. DOI: 10.1016/j.jtho.2019.06.016. View

19.

Matsushita H, Hasegawa K, Oda K, Yamamoto S, Asada K, Karasaki T . Neoantigen load and HLA-class I expression identify a subgroup of tumors with a T-cell-inflamed phenotype and favorable prognosis in homologous recombination-proficient high-grade serous ovarian carcinoma. J Immunother Cancer. 2020; 8(1). PMC: 7254153. DOI: 10.1136/jitc-2019-000375. View

20.

Yarchoan M, Johnson 3rd B, Lutz E, Laheru D, Jaffee E . Targeting neoantigens to augment antitumour immunity. Nat Rev Cancer. 2017; 17(4):209-222. PMC: 5575801. DOI: 10.1038/nrc.2016.154. View